CVS Health announced on March 24, 2026 that it has reached a proposed settlement agreement with the Federal Trade Commission (FTC) over its insulin pricing practices. The settlement follows the FTC’s administrative complaint, filed on September 20 2024, that accuses CVS’s Caremark PBM of engaging in spread‑pricing and rebate practices that may have inflated insulin costs for consumers and health plans.
The FTC’s investigation into pharmacy benefit managers began in June 2022 and has targeted a range of PBMs, including CVS Caremark, Express Scripts, and UnitedHealth’s Optum Rx. A key precedent is the February 4 2026 settlement with Express Scripts, which required the PBM to delink compensation from list prices and to offer plan sponsors options to move away from rebate guarantees and spread pricing. CVS is expected to adopt similar reforms, including transparent pricing and a shift away from rebate‑driven models.
While the terms of CVS’s settlement remain undisclosed, the company’s management has indicated that the agreement will likely require significant changes to its pricing and rebate structures for insulin sold through its pharmacy network and PBM contracts. These changes could compress margins in the short term, as the PBM business model traditionally relies on rebates and spread pricing to generate revenue.
In its February 10 2026 Q4 2025 earnings release, CVS CEO David Joyner noted that the company’s “adjusted earnings per share of $1.09 beat analyst expectations of $1.00, a $0.09 or 9% beat, driven by disciplined cost management and a favorable mix of high‑margin pharmacy services.” The company reaffirmed its 2026 adjusted EPS guidance of $7.00 to $7.20, but lowered its cash‑flow guidance to at least $9.0 billion from $10.0 billion, reflecting the anticipated impact of regulatory changes.
Analysts and investors are closely monitoring the settlement’s outcome, as it could reshape the PBM industry’s pricing dynamics and affect CVS’s competitive position. The FTC’s actions are part of a broader effort to increase transparency and reduce inflated drug costs, and the company’s willingness to negotiate a settlement signals its intent to comply while preserving its core pharmacy and health‑services operations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.